Robert F. Williamson is a seasoned executive with a background in business and finance. 

He is currently on the board of Pharmasset, Inc. (NASDAQ: VRUS) and is Executive Chairman of privately held Strategic Enzyme Applications, Inc. (SEA).   Previously he was Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology - which he sold to Protein Design Labs (NASDAQ: PDLI), and Chief Operating Officer of Pangea / DoubleTwist, Inc. - which was acquired in part by Merck (NYSE: MRK) and Hitachi (NYSE: HIT).  Before consulting to and managing life sciences companies, Mr. Williamson was a partner with The Boston Consulting Group, Inc., where his clients included top global pharmaceutical and medical device companies with additional clients in high technology and energy.  Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, D.C.

Mr. Williamson received a B.A. in Economics from Pomona College and an M.B.A. from Stanford Graduate School of Business.